Speaking at the meeting, President Barry Weiner pointed out that Enzo this past year, among other actions, has accomplished the following;
- Enzo Life Sciences has been transformed into a global manufacturer and marketer of Life Science products, that is now poised for growth organically and via acquisitions.
- Enzo Clinical Labs has enjoyed expanded revenues and it has embarked upon a program to develop broader capabilities in the rapidly growing field of molecular diagnostics.
- Enzo Therapeutics is focusing on treatments it believes have the greatest immediate opportunities, including Alequel™, an oral therapy for Crohn’s disease, and Optiquel™, an oral peptide for autoimmune uveitis, an eye disease.
“In addition, we are realizing positive results from our two operating units, Enzo Clinical Labs and Enzo Life Sciences, along with growing royalty and licensing revenues from our Intellectual Property estate,” Mr. Weiner noted. “Together with strong new management, we are solidly positioned for further progress.
At the meeting, shareholders elected Mr. Weiner, Melvin F. Lazar and Dr. Bernard Kastin as Class II Directors for a term of three years, and ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo’s Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 25,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for uveitis, Crohn's Disease, and NASH (non-alcoholic steatohepatitis), and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo’s Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company’s technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 200 patents worldwide, and has pending applications for over 180 more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
###
Contact:
For: Enzo Biochem, Inc.
Steve Anreder, 212-532-3232 Or Michael Wachs, CEOcast, Inc., 212-732-4300